TİROİD VE KARACİĞER

1. Sellin JH, Vasilopoulou-Sellin R. The gastrointestinal
tract and liver in thyrotoxicosis. In Brauerman LE, Utiger
RD. eds. Werner&Ingbar’s the Thyroid: A fundamental
and clinical text. 8th ed. Philadelphia, Lippincott
Williams&Wilkins, 2000; 622-26.
2. Sheridan P. Thyroid hormones and the liver. Clin
Gastroenterol 1983; 12: 797-818.
3. Reyes H, Levi AJ, Gatmaitan Z, Arias IM. Studies of Y
and Z, two hepatic cytoplasmic organic anion-binding
proteins: effect of drugs, chemicals, hormones, and
cholestasis. J Clin Invest 1971; 50: 2242-52.
4. Gartner LM, Arias IM. Hormonal control of hepatic
bilirubin transport and conjugation. Am J Physiol 1972;
222: 1091-9.
5. Van Steenbergen W, Fevery J, De Groote J. Thyroid
hormones and the hepatic handling of bilirubin. II.
Effects of hypothyroidism and hyperthyroidism on the
apparent maximal biliary secretion of bilirubin in the
Wistar rat. J Hepatol 1988; 7: 229-38.
CERRAHPAŞA TIP DERGİSİ Cilt (Sayı) 36 (4)
210
6. Layden TJ, Boyer JL. The effect of thyroid hormone on
bile salt-independent bile flow and Na+, K+ -ATPase
activity in liver plasma membranes enriched in bile
canaliculi. J Clin Invest 1976; 57: 1009-18.
7. Van Steenbergen W, Fevery J, De Vos R, Leyten R,
Heirwegh KP, De Groote J. Thyroid hormones and the
hepatic handling of bilirubin. I. Effects of
hypothyroidism and hyperthyroidism on the hepatic
transport of bilirubin mono- and diconjugates in the
Wistar rat. Hepatology 1989; 9: 314-21.
8. Iossa S, Liverini G, Barletta A. Relationship between the
resting metabolic rate and hepatic metabolism in rats:
effect of hyperthyroidism and fasting for 24 hours. J
Endocrinol 1992; 135: 45-51.
9. Magnusson I, Wennlund A, Chandramouli V, et al.
Fructose-6-phosphate cycling and the pentose cycle in
hyperthyroidism. J Clin Endocrinol Metab 1990; 70: 461-
6.
10. Gebhard RL, Stone BG, Andreini JP, Duane WC, Evans
CD, Prigge W. Thyroid hormone differentially augments
biliary sterol secretion in the rat. I. The isolated-perfused
liver model. J Lipid Res 1992; 33: 1459-66.
11. Sellin JH, Vasilopoulou-Sellin R. The gastrointestinal
tract and liver in hypothyroidism. In Brauerman LE,
Utiger RD. eds. Werner&Ingbar’s the Thyroid: A
fundamental and clinical text. 8th ed. Philadelphia,
Lippincott Williams&Wilkins, 2000; 795-99.
12. Pauletzki J, Stellaard F, Paumgartner G. Bile acid
metabolism in human hyperthyroidism. Hepatology 1989;
9: 852-5.
13. Babb RR. Associations between diseases of the thyroid
and the liver. Am J Gastroenterol 1984; 79: 421-3.
14. Huang MJ, Liaw YF. Clinical associations between
thyroid and liver diseases. J Gastroenterol Hepatol 1995;
10: 344-50.
15. Huang MJ, Liaw YF. Thyroxine-binding globulin in
patients with chronic hepatitis B virus infection: different
implications in hepatitis and hepatocellular carcinoma.
Am J Gastroenterol 1990; 85: 281-4.
16. Ross DS, Daniels GH, Dienstag JL, Ridgway EC.
Elevated thyroxine levels due to increased thyroxinebinding
globulin in acute hepatitis. Am J Med 1983; 74:
564-9.
17. L'Age M, Meinhold H, Wenzel KW, Schleusener H.
Relations between serum levels of TSH, TBG, T4, T3,
rT3 and various histologically classified chronic liver
diseases. J Endocrinol Invest 1980; 3: 379-83.
18. Gardner DF, Carithers RL Jr, Utiger RD. Thyroid
function tests in patients with acute and resolved hepatitis
B virus infection. Ann Intern Med 1982; 96: 450-2.
19. Van Thiel DH, Smith WI Jr, Wight C, Abuid J. Elevated
basal and abnormal thyrotropin-releasing hormoneinduced
thyroid-stimulating hormone secretion in chronic
alcoholic men with liver disease. Alcohol Clin Exp Res
1979; 3: 302-8.
20. Chopra IJ, Solomon DH, Chopra U, Young RT, Chua
Teco GN. Alterations in circulating thyroid hormones and
thyrotropin in hepatic cirrhosis: Evidence for
euthyroidism despite subnormal serum triiodothyronine. J
Clin Endocrinol Metab 1974; 39: 501-11.
21. Schlienger JL. Thyroid status in fifty patients with
alcoholic cirrhosis. Z Gasteroenterol 1979; 17: 452-61.
22. Ain KB, Refetoff S. Relationship of oligosaccharide
modification to the cause of serum thyroxine-binding
globulin excess. J Clin Endocrinol Metab 1988; 66:1037-
43
23. Nomura S, Pittman CS, Chambers JB Jr, Buck MW,
Shimizu T. Reduced peripheral conversion of thyroxine
to triiodothyronine in patients with hepatic cirrhosis. J
Clin Invest 1975; 56: 643-52.
24. Faber J, Thomsen HF, Lumholtz IB, Kirkegaard C,
Siersbaek-Nielsen K, Friis T. Kinetic studies of
thyroxine, 3,5,3'-triiodothyronine, 3,3,5'-triiodothyronine,
3', 5'-diiodothyronine, 3,3'-diiodothyronine, and 3'-
monoiodothyronine in patients with liver cirrhosis. J Clin
Endocrinol Metab 1981; 53: 978-84.
25. Chopra IJ. An assessment of daily production and
significance of thyroidal secretion of 3, 3', 5'-
triiodothyronine (reverse T3) in man. J Clin Invest 1976;
58: 32-40.
26. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess
G, Horsch A, Hadziyannis S. Thyroid abnormalities in
chronic viral hepatitis and their relationship to interferon
alfa therapy. Hepatology 1997; 26: 206-10.
27. Marine D, Lenhart CH. Pathological anatomy of
exophthalmic goiter: The anatomical and physiological
relations of the thyroid gland to the disease; the treatment.
Arch Intern Med 1911; 8:265-316.
28. Beaver DC, Pemberton J deJ. The pathologic anatomy of
the liver in exophthalmic goiter. Ann Intern Med 1933; 7:
687-708.
29. Cameron GR, Karuntaratne WAE. Liver changes in
exophthalmic goiter. J Path Bact 1935; 41: 267-93.
30. Moschcowitz E. Pathogenesis of cirrhosis of the liver
occurring in patients with diffuse toxic goiter. Arch Intern
Med 1946; 78: 497-530.
31. Piper J, Paulsen E: Liver biopsy in thyrotoxicosis. Acta
Med Scand 1947; 127: 439-45.
32. Movitt ER, Gerstl B, Davis AE. Needle liver biopsy in
thyrotoxicosis. Arch Intern Med 1953; 91: 729-39.
33. Klion FM, Segal R, Schaffner F. The effect of altered
thyroid function on the ultrastructure of the human liver.
Am J Med 1971; 50: 317-24.
34. Sheridan P. Thyroid hormones and the liver. Clin
Gastroenterol 1983; 12:797-818.
35. Huang MJ, Liaw YF. Clinical associations between thyroid
and liver diseases. J Gastroenterol Hepatol 1995; 10: 344-
50.
Ekim-Aralık 2005 TİROİD VE KARACİĞER; ÖZDEMİR
211
36. Fong TL, McHutchison JG, Reynolds TB.
Hyperthyroidism and hepatic dysfunction. A case series
analysis. J Clin Gastroenterol 1992; 14: 240-4.
37. Lorenz G, Meng W. Bioptical liver changes in florid
hyperthyreosis. Acta Hepatogastroenterol 1975; 22: 22-5.
38. Klion FM, Segal R, Schaffner F: The effect of altered
thyroid function on the ultrastructure of the human liver Am
J Med 1971; 50: 317-324.
39. Sola J, Pardo-Mindan FJ, Zozaya J, Quiroga J, Sangro B,
Prieto J. Liver changes in patients with hyperthyroidism
Liver 1991; 11: 193-7.
40. Imberti R, Vairetti M, Gualea MR, Feletti F, Poma G,
Richelmi P, Preseglio I, Bellomo G. The effects of
thyroid hormone modulation on rat liver injury associated
with ischemia-reperfusion and cold storage. Anesth
Analg 1998; 86: 1187-93.
41. Huang MJ, Li KL, Wei JS, Wu SS, Fan KD, Liaw YF.
Sequential liver and bone biochemical changes in
hyperthyroidism: prospective controlled follow-up study.
Am J Gastroenterol 1994; 89: 1071-6.
42. Dooner HP, Parada J, Aliaga C, Hoyl C. The liver in
thyrotoxicosis. Arch Intern Med 1967; 120: 25-32.
43. Greenberger WJ, Milligan FD, DeGroot LJ, Isselbacher KJ.
Jaundice and thyrotoxicosis in the absence of conestive
heart failure. Am J Med 1964; 36: 840-6.
44. Chen F. Liver function in thyrotoxicosis. J Formosan Med
Assoc 1963; 62: 130-9.
45. Thompson P Jr, Strum D, Boehm T, Wartofsky L.
Abnormalities of liver function tests in tyrotoxicosis Mil
Med 1978; 143: 548-51.
46. Gerlach U, Paul L, Latzel H. Isoenzymes of alkaline
phosphatase in hyperthyroidism. Enzymol Biol Clin
1970; 11: 251-6.
47. Ashkar FS, Miller R, Smoak WM 3rd, Gilson AJ. Liver
disease in hyperthyroidism. South Med J 1971; 64: 462-5.
48. Cooper DS, Kaplan MM, Ridgway EC, Maloof F,
Daniels GH. Alkaline phosphatase isoenzyme patterns in
hyperthyroidism. Ann Intern Med 1979; 90: 164-8.
49. Azizi F. gamma-Glutamyl transpeptidase levels in
thyroid disease. Arch Intern Med 1982; 142: 79-81.
50. Yao JD, Gross JB Jr, Ludwig J, Purnell DC. Cholestatic
jaundice in hyperthyroidism. Am J Med 1989; 86: 619-
20.
51. Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O,
Schwartz Sorensen N. Bone changes in hyperthyroidism:
interrelationships between bone morphometry, thyroid
function and calcium-phosphorus metabolism. Acta
Endocrinol 1977; 85: 515-25.
52. Barnes SC, Wicking JM, Johnston JD. Graves' disease
presenting with cholestatic jaundice. Ann Clin Biochem
1999; 36: 677-9.
53. Schussler GC, Schaffner F, Korn F. Increased serum
thyroid hormone binding and decreased free hormone in
chronic active liver disease. N Engl J Med 1978; 299:
510-5.
54. Sato N, Ohira H, Orikasa H, et al. Primary biliary
cirrhosis associated with painless thyroiditis. Intern Med
1999; 38: 244-8.
55. Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER.
Autoimmune associations in primary biliary cirrhosis.
Mayo Clin Proc 1982; 57: 365-70.
56. Crowe JP, Christensen E, Butler J, et al. Primary biliary
cirrhosis: The prevalence of hypothyroidism and its
relationship to thyroid autoantibodies and sicca
syndrome. Gastroenterology 1980; 78: 1437-41.
57. Thompson NP, Leader S, Jamieson CP, Burnham WR,
Burroughs AK. Reversible jaundice in primary biliary
cirrhosis due to hyperthyroidism. Gastroenterology 1994;
106: 1342-3.
58. Klein I, Levey GS. Unusual manifestations of
hypothyroidism. Arch Intern Med 1984; 144: 123-8.
59. Paradies G, Ruggiero FM, Dinoi P. The influence of
hypothyroidism on the transport of phosphate and on the
lipid composition in rat-liver mitochondria. Biochim
Biophys Acta 1991; 1070: 180-6.
60. Soboll S. Long-term and short-term changes in
mitochondrial parameters by thyroid hormones. Biochem
Soc Trans 1993; 21: 799-803.
61. Liverini G, Iossa S, Barletta A. Relationship between
resting metabolism and hepatic metabolism: effect of
hypothyroidism and 24 hours fasting. Horm Res 1992;
38: 154-9.
62. Comte B, Vidal H, Laville M, Riou JP. Influence of
thyroid hormones on gluconeogenesis from glycerol in
rat hepatocytes: a dose-response study. Metabolism 1990;
39: 259-63.
63. Marchesini G, Fabbri A, Bianchi GP, et al. Hepatic
conversion of amino nitrogen to urea nitrogen in
hypothyroid patients and upon L-thyroxine therapy.
Metabolism 1993; 42: 1263-9.
64. Clancy RL, Mackay IR. Myxoedematous ascites. Med J
Aust 1979; 2: 415-6.
65. Baker A, Kaplan M, Wolfe H. Central congestive fibrosis
of the liver in myxedema ascites. Ann Intern Med 1972;
77: 927-9.
66. de Castro F, Bonacini M, Walden JM, Schubert TT.
Myxedema ascites. Report of two cases and review of the
literature. J Clin Gastroenterol 1991; 13: 411-4.
67. Agnello V, De Rosa FG. Extrahepatic disease
manifestations of HCV infection: Some current issues. J
Hepatol 2004; 40: 341-52.
68. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic
manifestations of chronic hepatitis C. MULTIVIRC
Group. Multidepartment Virus C. Arthritis Rheum 1999;
42: 2204-12.
CERRAHPAŞA TIP DERGİSİ Cilt (Sayı) 36 (4)
212
69. Lunel F, Cacoub P. Treatment of autoimmune and
extrahepatic manifestations of hepatitis C virus infection.
J Hepatol 1999; 31 Suppl 1: 210-6.
70. Duclos-Vallee JC, Johanet C, Trinchet JC, et al. High
prevalence of serum antibodies to hepatitis C virus in
patients with Hashimoto's thyroiditis. BMJ 1994; 309:
846-7.
71. Bisot-Locard S, Bornet H, Rousset H, Cortey-Boennec L,
Bonnevial L, Vindimian M, Trepo C Low prevalence of
antibodies to hepatitis C virus in patients with
Hashimoto's thyroiditis. J Hepatol 1995; 23: 233-4.
72. Tran A, Quaranta JF, Benzaken S, et al. High prevalence
of thyroid autoantibodies in a prospective series of
patients with chronic hepatitis C before interferon
therapy. Hepatology 1993; 18: 253-7.
73. Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H,
Beaugrand M. Latent autoimmune thyroid disease in
patients with chronic HCV hepatitis. J Hepatol 1992; 16:
244-5.
74. Pawlotsky JM, Ben Yahia M, Andre C, et al.
Immunological disorders in C virus chronic active
hepatitis: a prospective case-control study. Hepatology
1994; 19: 841-8.
75. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders
in chronic hepatitis C. Am J Med 2004; 117: 10-3.
76. Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients
with hepatitis C infection. JAMA 1999; 281: 1588.
77. Antonelli A, Ferri C, Fallahi P, Nesti C, Zignego AL,
Maccheroni M. Thyroid cancer in HCV-related mixed
cryoglobulinemia patients. Clin Exp Rheumatol. 2002;
20: 693-6.
78. Montella M, Pezzullo L, Crispo A, et al. Risk of thyroid
cancer and high prevalence of hepatitis C virus. Oncol
Rep 2003; 10: 133-6.
79. Watanabe U, Hashimoto E, Hisamitsu T, Obata H,
Hayashi N. The risk factor for development of thyroid
disease during interferon-alpha therapy for chronic
hepatitis C. Am J Gastroenterol 1994; 89: 399-403.
80. Roti E, Minelli R, Giuberti T, et al. Multiple changes in
thyroid function in patients with chronic active HCV
hepatitis treated with recombinant interferon-alpha. Am J
Med 1996; 101: 482-7.
81. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al.
Increased risk of autoimmune thyroid disease in hepatitis
C vs hepatitis B before, during, and after discontinuing
interferon therapy. Arch Intern Med 1998; 158: 1445-8.
82. Lisker-Melman M, Di Bisceglie AM, Usala SJ,
Weintraub B, Murray LM, Hoofnagle JH. Development
of thyroid disease during therapy of chronic viral
hepatitis with interferon alfa. Gastroenterology 1992;
102: 2155-60.
83. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus
infection, alpha interferon therapy and thyroid
dysfunction. J Hepatol 1995; 22: 364-9.
84. Ward DL, Bing-You RG. Autoimmune thyroid
dysfunction induced by interferon-alpha treatment for
chronic hepatitis C: screening and monitoring
recommendations. Endocr Pract 2001; 7: 52-8.
85. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus
infection, alpha interferon therapy and thyroid
dysfunction. J Hepatol 1995; 22: 364-9.
86. Kiehne K, Kloehn S, Hinrichsen H, Gallwitz B, Monig H.
Thyroid autoantibodies and thyroid dysfunction during
treatment with interferon-alpha for chronic hepatitis C.
Endocrine 1997; 6: 231-4.
87. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and
thyroid function in patients with chronic active hepatitis
treated with recombinant interferon alpha-2a. Eur J
Endocrinol 1995; 132: 587-93.
88. Cooper DS. Antithyroid drugs for the treatment of
hyperthyroidism caused by Graves' disease. Endocrinol
Metab Clin North Am 1998; 27: 225-47.
89. Cooper DS, Goldminz D, Levin AA, et al.
Agranulocytosis associated with antithyroid drugs.
Effects of patient age and drug dose. Ann Intern Med
1983; 98: 26-29.
90. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of
Drugs and Other Chemicals an the Liver. 2nd ed.
Philadelphia, Lippincott Williams&Wilkins, 1999; 555-
588.
91. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ.
Hepatic injury during propylthiouracil therapy in patients
with hyperthyroidism. A cohort study. Ann Intern Med
1993; 118: 424-8.
92. Vitug AC, Goldman JM. Hepatotoxicity from antithyroid
drugs. Horm Res 1985; 21: 229-34.
93. Williams KV, Nayak S, Becker D, Reyes J, Burmeister
LA. Fifty years of experience with propylthiouracilassociated
hepatotoxicity: what have we learned? J Clin
Endocrinol Metab 1997; 82: 1727-33.
94. Gotta AW, Sullivan CA, Seaman J, Jean-Gilles B.
Prolonged intraoperative bleeding caused by
propylthiouracil-induced hypoprothrombinemia.
Anesthesiology 1972; 37: 562-3.
95. Blom H, Stolk J, Schreuder HB, von Blomberg-van der
Flier M. A case of carbimazole-induced intrahepatic
cholestasis. An immune-mediated reaction? Arch Intern
Med 1985; 145: 1513-5.
96. Arab DM, Malatjalian DA, Rittmaster RS. Severe
cholestatic jaundice in uncomplicated hyperthyroidism
treated with methimazole. J Clin Endocrinol Metab 1995;
80: 1083-5.
97. Kang H, Choi JD, Jung IG, et al. A case of methimazoleinduced
acute hepatic failure in a patient with chronic
hepatitis B carrier. Korean J Intern Med 1990; 5: 69-73